News Details - Moderna
WEBMar 26, 2024 · The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
News Details - Moderna
WEBMar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAugust 22, 2024. Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent...
News Details - Moderna
WEBSep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines …
Moderna's updated COVID-19 vaccine for 2024-25 approved in …
WEB3 days ago · Vaccine targets KP.2 variant, one of the latest offshoots of Omicron. Health Canada has authorized Moderna's updated COVID-19 vaccine, shown here in August 2024. (Moderna/The Canadian Press ...
News Details - Moderna
WEBJun 10, 2024 · Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19. mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older ...
Moderna Inc - The New York Times
WEBNews about Moderna Inc. Commentary and archival information about Moderna Inc from The New York Times.
News Details - Moderna
WEBJan 8, 2024 · Moderna will enter the RSV market with a strong competitive profile as the only pre-filled syringe product available at the time of launch, along with robust efficacy data, a well-established safety and tolerability profile, and widespread consumer awareness and demand established in 2023.
Moderna Says Its Booster Significantly Raises Antibodies …
WEBDec 20, 2021 · A booster shot of the Moderna coronavirus vaccine significantly raises the level of antibodies that can thwart the Omicron variant, the company announced on Monday.
Coronavirus (COVID-19) Update: FDA Takes Key Action by …
WEBJan 31, 2022 · Today, the U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for...